SI1325932T1 - - Google Patents

Info

Publication number
SI1325932T1
SI1325932T1 SI9830758T SI9830758T SI1325932T1 SI 1325932 T1 SI1325932 T1 SI 1325932T1 SI 9830758 T SI9830758 T SI 9830758T SI 9830758 T SI9830758 T SI 9830758T SI 1325932 T1 SI1325932 T1 SI 1325932T1
Authority
SI
Slovenia
Prior art keywords
vegf
vitro
antibodies
vegf antibodies
inhobit
Prior art date
Application number
SI9830758T
Other languages
English (en)
Inventor
Manuel The Walter Eliza H Baca
James A Wells
Leonard G Presta
Henry B Lowman
Yvonne Man-Yee Chen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1325932(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/908,469 external-priority patent/US6884879B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SI1325932T1 publication Critical patent/SI1325932T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Air Bags (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
SI9830758T 1997-04-07 1998-04-03 SI1325932T1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07
US08/908,469 US6884879B1 (en) 1997-04-07 1997-08-06 Anti-VEGF antibodies
EP03004199A EP1325932B9 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies

Publications (1)

Publication Number Publication Date
SI1325932T1 true SI1325932T1 (ja) 2005-08-31

Family

ID=27125626

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830758T SI1325932T1 (ja) 1997-04-07 1998-04-03

Country Status (26)

Country Link
US (2) US7060269B1 (ja)
EP (4) EP0973804B1 (ja)
JP (1) JP3957765B2 (ja)
KR (2) KR100816621B1 (ja)
CN (1) CN100480269C (ja)
AT (2) ATE349470T1 (ja)
AU (1) AU743758B2 (ja)
BR (1) BRPI9809387B8 (ja)
CA (1) CA2286330C (ja)
CY (3) CY2005008I2 (ja)
DE (5) DE69829891T2 (ja)
DK (2) DK0973804T3 (ja)
ES (2) ES2273415T3 (ja)
FR (2) FR05C0020I2 (ja)
GE (1) GEP20105118B (ja)
HK (2) HK1084402A1 (ja)
IL (1) IL132240A0 (ja)
LT (1) LTPA2005005I1 (ja)
LU (2) LU91167I2 (ja)
NL (2) NL300193I2 (ja)
NO (3) NO324264B1 (ja)
NZ (1) NZ500078A (ja)
PT (1) PT1325932E (ja)
SI (1) SI1325932T1 (ja)
TR (1) TR199903123T2 (ja)
WO (1) WO1998045331A2 (ja)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
EP1135498B1 (en) * 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
EP1579871A1 (en) * 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003035835A2 (en) * 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
PT1501369E (pt) 2002-04-26 2015-09-21 Genentech Inc Purificação de proteínas com base na não afinidade
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
WO2007066106A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004070016A2 (en) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. System for expression of genes in plants
WO2004080418A2 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
BRPI0410562B8 (pt) 2003-05-22 2021-05-25 Fralunhofer Usa Inc proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
KR20160114727A (ko) 2003-05-30 2016-10-05 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
AU2004265253B2 (en) 2003-07-28 2011-09-01 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
EP1730196B1 (en) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP1784427A2 (en) 2004-06-01 2007-05-16 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) * 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2006012500A2 (en) 2004-07-23 2006-02-02 Genentech, Inc. Crystallization of antibodies or fragments thereof
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
DK1802334T3 (da) * 2004-10-21 2012-10-15 Genentech Inc Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
AU2005318999B2 (en) 2004-12-22 2012-07-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP1833512A1 (en) * 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007009960A (es) 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2586459B1 (en) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
US20080045949A1 (en) * 2005-06-17 2008-02-21 Hunt Margaret M Method of treating degenerative spinal disorders
RU2423382C1 (ru) * 2005-06-20 2011-07-10 Дженентек, Инк. Композиции и способы диагностики и лечения опухоли
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007117264A2 (en) 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CA2629815C (en) * 2005-11-14 2014-08-12 University Of Southern California Integrin-binding small molecules
AU2006326417B2 (en) † 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
CN103360496B (zh) 2006-01-05 2015-11-18 健泰科生物技术公司 抗ephb4抗体及其使用方法
JP5368110B2 (ja) 2006-01-20 2013-12-18 ジェネンテック， インコーポレイテッド 抗エフリンｂ２抗体とその使用方法
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
CN101405030B (zh) * 2006-03-22 2013-03-13 霍夫曼-拉罗奇有限公司 针对血管内皮生长因子的抗体和针对人表皮生长因子2型受体的抗体在制备***的试剂盒中的应用
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20080106946A (ko) * 2006-03-29 2008-12-09 제넨테크, 인크. 종양의 진단 및 치료
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
HUE053612T2 (hu) 2006-06-16 2021-07-28 Regeneron Pharma Intravitreális bevitelre alkalmas VEGF-antagonista készítmények
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008011513A2 (en) 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
JP2010501498A (ja) 2006-08-21 2010-01-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｖｅｇｆ抗体による腫瘍治療
ES2557953T3 (es) 2006-09-29 2016-01-29 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar cáncer
AR063125A1 (es) 2006-10-04 2008-12-30 Genentech Inc Ensayo elisa para la deteccion de vegf
CN102006885A (zh) * 2006-10-20 2011-04-06 先灵公司 完全人源抗vegf抗体及其使用方法
DK2101807T3 (en) 2006-12-19 2016-08-29 Genentech Inc VEGF-SPECIFIC ANTAGONISTS FOR ADMINISTRATIVE AND NEOADVERTIVE TREATMENT AND TREATMENT OF TEMPERATURES IN EARLY STAGE
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
ZA200904482B (en) 2007-01-22 2010-09-29 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
ES2469743T3 (es) 2007-05-17 2014-06-18 Genentech, Inc. Inhibición de la metástasis tumoral por anticuerpos anti neuropilina 2
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
KR20150008503A (ko) 2007-10-30 2015-01-22 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
EP2217261B1 (en) * 2007-11-09 2015-10-07 Genentech, Inc. Activin receptor-like kinase-1 antagonist compositions and methods of use
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AR070865A1 (es) 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
EP2274008B1 (en) * 2008-03-27 2014-02-26 ZymoGenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
KR102095257B1 (ko) 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN102149825B (zh) * 2008-07-08 2015-07-22 Abbvie公司 ***素e2双重可变结构域免疫球蛋白及其用途
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
EP2321651B1 (en) 2008-07-23 2017-08-23 F. Hoffmann-La Roche AG Identification of subjects being susceptible to anti-angiogenesis therapy
JP5666447B2 (ja) 2008-08-14 2015-02-12 ジェネンテック， インコーポレイテッド 常在性タンパク質置換イオン交換メンブレンクロマトグラフィを用いた混入物除去方法
WO2010025414A2 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
WO2010027501A2 (en) 2008-09-05 2010-03-11 Duke University Anti-lipid antibodies
US20100068210A1 (en) 2008-09-10 2010-03-18 Ji Junyan A Compositions and methods for the prevention of oxidative degradation of proteins
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN110317272A (zh) 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
KR101719376B1 (ko) 2008-11-05 2017-03-23 제넨테크, 인크. 연령-관련 황반 변성에서 유전자 다형성
CN102223897B (zh) 2008-11-22 2015-09-23 霍夫曼-拉罗奇有限公司 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
KR20140020368A (ko) 2008-12-23 2014-02-18 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
WO2010081838A2 (en) 2009-01-14 2010-07-22 Novartis Ag Sterile prefilled container
EP2393513B1 (en) 2009-02-06 2016-10-19 The General Hospital Corporation Methods of treating vascular lesions
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and their methods of use
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
US20120189701A1 (en) 2009-03-13 2012-07-26 Desai Neil P Combination therapy with thiocolchicine derivatives
CA2753988C (en) 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
BRPI1010297A2 (pt) 2009-04-07 2017-06-06 Roche Glycart Ag anticorpos biespecíficos trivalentes.
US20120135005A1 (en) * 2009-04-16 2012-05-31 Harding Fiona A ANTI-TNF-a ANTIBODIES AND THEIR USES
TW201106969A (en) * 2009-04-20 2011-03-01 Genentech Inc Adjuvant cancer therapy
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US8496938B2 (en) 2009-05-08 2013-07-30 Vaccinex, Inc. Anti-CD100 neutralizing neutralizing antibodies and methods of using the same
JP5383905B2 (ja) 2009-05-08 2014-01-08 ジェネンテック， インコーポレイテッド ヒト化抗ｅｇｆｌ７抗体とその使用方法
EP2443234B1 (en) 2009-06-15 2018-08-15 Icon Genetics GmbH Nicotiana benthamiana plants deficient in xylosyltransferase activity
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
BR112012000735A2 (pt) 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
AR078060A1 (es) 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
JP2013500993A (ja) 2009-07-31 2013-01-10 ジェネンテック， インコーポレイテッド Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
CA2770321A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
NZ598131A (en) * 2009-08-15 2014-08-29 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
PL2473617T3 (pl) 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
US8642515B2 (en) 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
US20110064670A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
RU2577726C2 (ru) 2009-10-21 2016-03-20 Дженентек, Инк. Генетические полиморфизмы при возрастной дегенерации желтого пятна
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
DK2516465T3 (en) 2009-12-23 2016-06-06 Hoffmann La Roche ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
WO2011090719A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN103237810A (zh) 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
SI2550018T1 (sl) 2010-03-22 2019-05-31 F. Hoffmann-La Roche Ag Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
US20130156755A1 (en) 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
KR101827855B1 (ko) 2010-05-17 2018-02-12 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
KR101869987B1 (ko) 2010-05-28 2018-07-20 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MY162903A (en) 2010-06-04 2017-07-31 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CA2802756C (en) 2010-06-24 2021-05-04 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2012003437A1 (en) 2010-07-02 2012-01-05 Genentech, Inc. Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CN104965084B (zh) 2010-07-19 2017-09-29 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
AU2011329127B2 (en) 2010-11-15 2015-09-03 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
CN103476795B (zh) 2011-03-29 2016-07-06 罗切格利卡特公司 抗体Fc变体
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6143739B2 (ja) 2011-04-01 2017-06-07 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びベムラフェニブの組み合わせ、及び使用方法
CN103781798B (zh) 2011-04-20 2018-03-13 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
US9181532B2 (en) 2011-07-29 2015-11-10 Icon Genetics Gmbh Production of galactosylated N-glycans in plants
BR112014003599A2 (pt) 2011-08-17 2018-04-17 Genentech Inc método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
AU2012320847B2 (en) 2011-10-04 2018-03-08 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
CN107080843A (zh) * 2011-10-13 2017-08-22 爱尔皮奥治疗有限公司 眼病的治疗
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
US9988424B2 (en) 2011-12-05 2018-06-05 Duke University Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
WO2013106765A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
EP2819700B1 (en) 2012-02-27 2016-12-21 Universitat de Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
DK2825558T3 (da) 2012-03-13 2019-07-22 Hoffmann La Roche Kombinationsterapi til behandling af ovariecancer
CN109880867A (zh) 2012-03-27 2019-06-14 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
CN104271157A (zh) 2012-03-30 2015-01-07 霍夫曼-拉罗奇有限公司 用于治疗癌症的诊断方法和组合物
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR20200079568A (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
PL3679922T3 (pl) 2012-06-01 2022-01-03 Novartis Ag Strzykawka
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
EA032192B1 (ru) 2012-07-13 2019-04-30 Роше Гликарт Аг Биспецифическое антитело к vegf/ang-2, нуклеиновая кислота, кодирующая это антитело, вектор, содержащий нуклеиновую кислоту, клетка-хозяин, способ получения биспецифического антитела и содержащая его фармацевтическая композиция
KR20190088571A (ko) 2012-08-07 2019-07-26 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법
SG11201502076SA (en) 2012-09-19 2015-04-29 Genentech Inc Methods and compositions for preventing norleucine misincorporation into proteins
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
KR20150085064A (ko) 2012-11-16 2015-07-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 단백질 화학적 변형을 위한 피크테 스펭글러 결합
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EA201591176A1 (ru) 2012-12-18 2016-02-29 Новартис Аг Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
AU2014205369B2 (en) 2013-01-11 2018-08-09 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
WO2014145091A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
SG11201509596YA (en) 2013-05-23 2015-12-30 Five Prime Therapeutics Inc Methods of treating cancer
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
KR20210104166A (ko) 2013-06-25 2021-08-24 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
BR112016000546A2 (pt) 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR102354787B1 (ko) 2013-10-25 2022-01-24 악셀레론 파마 인코포레이티드 섬유화 질환을 치료하기 위한 엔도글린 펩티드
WO2015071348A1 (en) 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
KR20150132581A (ko) * 2013-12-31 2015-11-25 재단법인 생물기술개발중심 항-vegf 항체 및 그것의 용도
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
MX2016010505A (es) 2014-02-14 2017-04-13 S Chi Andrew Metodos mejorados para el tratamiento de canceres vascularizantes.
WO2015124588A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
US10590455B2 (en) 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
EP3116891B1 (en) 2014-03-10 2020-02-12 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
JP6802069B2 (ja) 2014-05-12 2020-12-16 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2953154C (en) 2014-07-09 2023-03-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
CN105330739B (zh) * 2014-08-12 2020-12-25 中美华世通生物医药科技（武汉）有限公司 与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
BR112017004393A2 (pt) 2014-09-15 2018-02-27 Genentech Inc formulações de anticorpo
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
CA2966042A1 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
LT3230316T (lt) 2014-12-11 2022-02-10 Bayer Healthcare Llc Gydymas su amžiumi susijusios geltonosios dėmės degeneracijos su mažu aktyvios choroidinės neovaskuliarizacijos pažeidimu
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
AU2015369624A1 (en) 2014-12-23 2017-06-08 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10544224B2 (en) 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
PL3328886T3 (pl) 2015-07-29 2021-02-08 Allergan, Inc. Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
HU231463B1 (hu) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
CA2992788A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
EP3337508A4 (en) * 2015-08-21 2019-04-03 Immunomedics, Inc. MONOCLONAL ANTI-HLA-DR ANTIBODY FOR SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANT TUMORS
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
EP3353196B1 (en) 2015-09-22 2022-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
CN108602881A (zh) 2015-10-30 2018-09-28 豪夫迈·罗氏有限公司 抗-因子d抗体制剂
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
EP3377100A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
KR20180105123A (ko) 2015-11-18 2018-09-27 에스아이오2 메디컬 프로덕츠, 인크. 안과 제제용 제약 패키지
RS64725B1 (sr) 2015-12-03 2023-11-30 Regeneron Pharma Postupci dovođenja u vezu genskih varijanti sa kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije lečenih anti- vegf-om
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
WO2017165681A1 (en) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
SG11201808562SA (en) 2016-03-29 2018-10-30 Geltor Inc Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
EP3481963A1 (en) 2016-07-08 2019-05-15 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
ES2836286T3 (es) * 2016-08-23 2021-06-24 Medimmune Ltd Anticuerpos anti-VEGF-A y usos de los mismos
WO2018070390A1 (ja) 2016-10-12 2018-04-19 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
JP7256127B2 (ja) 2017-03-01 2023-04-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
JP2020511516A (ja) * 2017-03-24 2020-04-16 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 組換え抗体断片の精製方法
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性***PPARγ激动剂
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
KR102607655B1 (ko) 2017-05-19 2023-11-28 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 리폴딩된 재조합 인간화 라니비주맙의 제조 방법
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
JP7163288B2 (ja) 2017-07-04 2022-10-31 第一三共株式会社 視細胞変性を伴う網膜変性疾患用薬
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
JP2021500355A (ja) 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド 抗血管新生薬剤療法のための診断方法
US20210071149A1 (en) 2017-12-19 2021-03-11 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
CN111511400A (zh) 2017-12-29 2020-08-07 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
CN110283248B (zh) * 2018-01-05 2020-07-28 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
JP7005772B2 (ja) 2018-02-06 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 眼科疾患の処置
EA202091710A1 (ru) 2018-03-09 2021-02-16 Агенус Инк. Антитела против cd73 и способы их применения
WO2019201195A1 (zh) 2018-04-16 2019-10-24 上海岸阔医药科技有限公司 预防或***疗法副作用的方法
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019229116A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
AU2019293047A1 (en) 2018-06-29 2021-01-28 Gensun Biopharma Inc. Antitumor immune checkpoint regulator antagonists
EP3818078B1 (en) 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Methods of producing recombinant proteins
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
KR20210079311A (ko) 2018-10-18 2021-06-29 제넨테크, 인크. 육종성 신장암에 대한 진단과 치료 방법
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN109134651B (zh) * 2018-12-03 2019-02-22 上海复宏汉霖生物技术股份有限公司 一种抗vegf的单克隆抗体及其制备方法和应用
US20200207812A1 (en) 2018-12-07 2020-07-02 Coherus Biosciences, Inc. Methods for producing recombinant proteins
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
US20220154212A1 (en) 2019-03-13 2022-05-19 Vascular Biogenics Ltd. Methods of anti-tumor therapy
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
US20220211847A1 (en) 2019-05-06 2022-07-07 Medimmune Limited Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
JP2022540571A (ja) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
EP4007808A1 (en) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2021072210A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
WO2021072182A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
IL293241A (en) 2019-11-25 2022-07-01 Akeso Biopharma Inc Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
US20230374447A1 (en) 2020-10-05 2023-11-23 Protalix Ltd. Dicer-like knock-out plant cells
JP2023545514A (ja) 2020-10-15 2023-10-30 ジェネンテック， インコーポレイテッド 治療薬の長時間作用型送達のためのバーシカン（ｖｇ１）のヒアルロン酸結合誘導体
AU2021377810A1 (en) 2020-11-13 2023-05-11 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
KR20230117179A (ko) 2020-12-01 2023-08-07 아카우오스, 인크. 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
AU2022214491A1 (en) 2021-01-28 2023-09-14 Janssen Biotech, Inc. Psma binding proteins and uses thereof
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
BR112023018457A2 (pt) 2021-03-12 2023-10-10 Akeso Biopharma Inc Combinação farmacêutica contendo anticorpo biespecífico anti-pd-1-anti-vegfa e uso da mesma
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
JP2024519888A (ja) 2021-05-28 2024-05-21 上海瑞宏迪医薬有限公司 カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
AU2022302170A1 (en) 2021-07-02 2023-12-21 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023010095A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
EP4386004A1 (en) 2021-08-13 2024-06-19 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
CN117679505A (zh) 2022-09-09 2024-03-12 中山康方生物医药有限公司 药物组合及用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS6289971A (ja) * 1985-06-13 1987-04-24 Toray Ind Inc 静電潜像用液体現像剤
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2345497A1 (en) * 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
SK281142B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP1238986B1 (en) * 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
SI1787999T1 (sl) * 1997-04-07 2010-12-31 Genentech Inc Anti-VEGF protitelesa
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies

Also Published As

Publication number Publication date
HK1023577A1 (en) 2000-09-15
AU7100798A (en) 1998-10-30
DK0973804T3 (da) 2007-05-07
DE69829891D1 (de) 2005-05-25
JP2001509817A (ja) 2001-07-24
BR9809387A (pt) 2001-09-11
FR07C0017I1 (fr) 2007-04-27
NO2007015I1 (no) 2008-01-14
WO1998045331A3 (en) 1998-12-03
JP3957765B2 (ja) 2007-08-15
EP1787999A1 (en) 2007-05-23
FR07C0017I2 (fr) 2008-05-09
KR100816621B1 (ko) 2008-03-24
BRPI9809387B1 (pt) 2016-11-22
ES2273415T3 (es) 2007-05-01
LU91320I9 (ja) 2018-12-31
NL300278I2 (nl) 2007-10-01
DK1325932T5 (da) 2005-10-03
EP1325932A3 (en) 2003-10-29
KR20080003452A (ko) 2008-01-07
NO2007014I1 (no) 2008-01-14
CY2007012I1 (el) 2009-11-04
LU91167I2 (fr) 2005-06-20
CA2286330C (en) 2008-06-10
LU91320I2 (fr) 2007-04-30
DE69836729D1 (de) 2007-02-08
EP1650220A3 (en) 2006-05-03
CY2007012I2 (el) 2009-11-04
CY2005008I2 (el) 2017-11-14
AU743758B2 (en) 2002-02-07
EP0973804A2 (en) 2000-01-26
TR199903123T2 (xx) 2000-05-22
EP1787999B1 (en) 2010-08-04
CY2005008I1 (el) 2009-11-04
KR20080003453A (ko) 2008-01-07
GEP20105118B (en) 2010-11-25
WO1998045331A2 (en) 1998-10-15
EP1325932B9 (en) 2006-07-19
ATE349470T1 (de) 2007-01-15
NL300193I2 (nl) 2005-10-03
FR05C0020I1 (ja) 2005-05-27
CN1259962A (zh) 2000-07-12
NO2007014I2 (no) 2011-02-21
CA2286330A1 (en) 1998-10-15
DE122007000021I1 (de) 2007-05-24
US7297334B2 (en) 2007-11-20
CY1106382T1 (el) 2010-07-28
NO994869D0 (no) 1999-10-06
EP1650220A2 (en) 2006-04-26
LTPA2005005I1 (lt) 2017-11-27
HK1084402A1 (en) 2006-07-28
DE69836729T2 (de) 2007-12-13
NZ500078A (en) 2001-10-26
KR100870353B1 (ko) 2008-11-25
EP1325932B1 (en) 2005-04-20
EP1650220B1 (en) 2007-09-05
NO2007015I2 (ja) 2011-11-28
IL132240A0 (en) 2001-03-19
EP0973804B1 (en) 2006-12-27
NL300278I1 (nl) 2007-06-01
ATE293640T1 (de) 2005-05-15
EP1325932A2 (en) 2003-07-09
DE69829891T2 (de) 2005-10-06
FR05C0020I2 (fr) 2008-05-09
DE122005000050I1 (de) 2005-12-29
CN100480269C (zh) 2009-04-22
NO994869L (no) 1999-12-06
DE122005000026I1 (de) 2005-08-04
DK1325932T3 (da) 2005-05-30
NL300193I1 (nl) 2005-07-01
BRPI9809387B8 (pt) 2021-05-25
PT1325932E (pt) 2005-06-30
NO324264B1 (no) 2007-09-17
ES2236634T3 (es) 2005-07-16
US20050112126A1 (en) 2005-05-26
US7060269B1 (en) 2006-06-13

Similar Documents

Publication Publication Date Title
NO2019045I1 (no) Ranibizumab - Forlenget SPC
NO2007015I2 (ja)